CHRS · Coherus Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $3.81M | - | $3.72M | $3.40M | $2.65M | - | $20.74M | $28.37M | $34.59M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $21.54M | - | $27.25M | $26.31M | $24.36M | - | $21.68M | $21.95M | $28.47M | - |
| SG&A | $23.10M | - | $24.93M | $26.04M | $26.02M | - | $34.74M | $35.16M | $56.53M | - |
| Total Operating Expenses | $48.46M | - | $55.90M | $55.74M | $53.03M | - | $77.16M | $85.49M | $119.59M | - |
| D&A | $881.0K | - | $300.0K | $300.0K | $400.0K | - | $400.0K | $500.0K | $600.0K | - |
| Operating Income | ($36.15M) | - | ($44.33M) | ($45.49M) | ($45.44M) | - | ($6.39M) | ($20.51M) | ($42.52M) | - |
| Interest Expense | $2.19M | - | $2.33M | $2.28M | $2.15M | - | $5.36M | $5.33M | $11.12M | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($38.33M) | - | ($35.53M) | $297.77M | ($56.57M) | - | ($10.75M) | ($12.92M) | $102.88M | - |
| EPS - Basic | ($0.28) | - | ($0.31) | $2.57 | ($0.49) | - | ($0.09) | ($0.11) | $0.91 | - |
| EPS - Diluted | ($0.28) | - | ($0.31) | $2.57 | ($0.49) | - | ($0.09) | ($0.11) | $0.83 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $115.24M | $88.88M | $103.35M | $216.89M | $82.41M | $125.99M | $97.69M | $159.24M | $259.77M | $102.89M |
| Accounts Receivable | $22.06M | $17.82M | $9.24M | $5.11M | $60.49M | $111.32M | $167.56M | $175.25M | $251.95M | $260.52M |
| Inventory | $4.83M | $3.17M | $2.05M | $4.51M | $3.52M | $70.09M | $47.64M | $62.16M | $61.98M | $62.60M |
| Accounts Payable | $11.48M | $9.91M | $24.89M | $37.62M | $40.93M | $28.46M | $21.89M | $76.82M | $38.29M | $35.22M |
| Current Assets | $206.03M | $206.71M | $460.95M | $380.20M | $310.18M | $341.58M | $369.02M | $557.93M | $627.48M | $475.63M |
| Total Assets | $266.02M | $258.34M | $516.52M | $439.46M | $371.07M | $448.53M | $505.00M | $674.86M | $763.54M | $629.60M |
| Current Liabilities | $132.33M | $140.39M | $372.30M | $263.63M | $255.04M | $282.98M | $295.57M | $463.00M | $538.30M | $331.77M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $187.40M | $197.33M | $428.75M | $319.64M | $554.54M | $580.52M | $592.97M | $758.96M | $845.39M | $823.03M |
| Stockholders' Equity | $78.62M | $61.01M | $87.77M | $119.83M | ($183.47M) | ($131.99M) | ($87.97M) | ($84.11M) | ($81.84M) | ($193.43M) |
| Retained Earnings | ($1.42B) | ($1.38B) | ($1.35B) | ($1.31B) | ($1.61B) | ($1.55B) | ($1.50B) | ($1.49B) | ($1.48B) | ($1.58B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($57.89M) | - | - | - | ($25.83M) | - | - | - | ($46.77M) | - |
| Investing Cash Flow | $30.66M | - | - | - | ($17.49M) | - | - | - | $202.76M | - |
| Financing Cash Flow | $53.59M | - | - | - | ($264.0K) | - | - | - | $887.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -14.4% | - | -6.9% | 67.8% | -15.2% | - | -2.1% | -1.9% | 13.5% | - |
| Return on equity | -48.7% | - | -40.5% | 248.5% | 30.8% | - | 12.2% | 15.4% | -125.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.56 | 1.47 | 1.24 | 1.44 | 1.22 | 1.21 | 1.25 | 1.21 | 1.17 | 1.43 |
| Quick ratio | 1.52 | 1.45 | 1.23 | 1.43 | 1.20 | 0.96 | 1.09 | 1.07 | 1.05 | 1.24 |
| Cash ratio | 0.87 | 0.63 | 0.28 | 0.82 | 0.32 | 0.45 | 0.33 | 0.34 | 0.48 | 0.31 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -16.5x | - | -19.1x | -20.0x | -21.1x | - | -1.2x | -3.8x | -3.8x | - |
| Equity multiplier | 3.38 | 4.23 | 5.88 | 3.67 | -2.02 | -3.40 | -5.74 | -8.02 | -9.33 | -3.26 |
| Liabilities / Assets | 0.70 | 0.76 | 0.83 | 0.73 | 1.49 | 1.29 | 1.17 | 1.12 | 1.11 | 1.31 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.79 | - | 1.82 | 0.75 | 0.75 | - | 0.44 | 0.46 | 0.56 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 462d | - | 201d | 485d | 484d | - | 838d | 800d | 654d | - |
| Days payable outstanding | 1099d | - | 2442d | 4045d | 5631d | - | 385d | 988d | 404d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | 0.3x | - | - | - | - | 2.9x | - |
| P / B | 2.9x | - | 2.2x | 0.7x | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 20.4% | - | -594.1% | -121.8% | -6.8% | - | 80.0% | 40.6% | 37.2% | - |
| Net income growth (YoY) | 32.2% | - | -230.5% | - | - | - | 72.9% | 69.9% | - | - |
| EPS growth (YoY) | 42.9% | - | -244.4% | - | - | - | 78.0% | 77.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | 29.7% | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | -124.2% | 31.8% | 34.2% | 51.9% | 58.4% | -40.8% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Coherus BioSciences against the 5 most active filers in the same SIC group.